Brief: Axovant Gene Therapies Announces Pricing Of $65 Million Public Offering
Feb 19 (Reuters) - Axovant Gene Therapies Ltd AXGT.O :
* AXOVANT GENE THERAPIES ANNOUNCES PRICING OF $65 MILLION
PUBLIC
OFFERING
* ANNOUNCED PRICING OF ITS UNDERWRITTEN PUBLIC OFFERING OF
14
MILLION OF COMMON SHARES AT A PRICE OF $3.75 PER SHARE
Source text for Eikon: ID:nGNX9Fv7dn
Further company coverage: AXGT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sio Gene Therapies
See all newsBrief: Sio Gene Therapies Inc - On March 14, Got Notice That Nasdaq Has Determined That Company's Common Stock Will Be Delisted From Nasdaq Capital Market
Brief: Sio Gene Therapies Announces Fiscal Third Quarter 2022 Financial Results
Brief: Sio Gene Therapies Inc. Announces Board Approval Of Plan Of Complete Liquidation, Dissolution
Brief: Sio Gene Therapies Announces Second Quarter Financial Results
Brief: Sio Gene Therapies Announces Fiscal First Quarter 2022 Financial Results